PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BD Medical Announced the U.S. Launch of the BD Ultra-Fine™ Nano™ 4mm Pen Needle with EasyFlow™ Technology - BD’s latest pen needle innovation designed to make injections easier for people with diabetes (NYSE: BDX) - DiabetesJournals.org / BD.com
BD Medical Announced the U.S. Launch of the BD Ultra-Fine™ Nano™ 4mm Pen Needle with EasyFlow™ Technology

 

NewswireToday - /newswire/ - Franklin Lakes, NJ, United States, 2013/06/21 - BD’s latest pen needle innovation designed to make injections easier for people with diabetes (NYSE: BDX) - DiabetesJournals.org / BD.com. NYSE: BDX

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Addition of EasyFlow™ Technology to BD Ultra-Fine™ Nano™ 4mm Pen Needles Increases Confidence and Convenience of Injections.

BD Medical, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, announced today the U.S. launch of the BD Ultra-Fine™ Nano™ 4mm Pen Needle with EasyFlow™ Technology. EasyFlow Technology makes it easier and faster for people with diabetes to give themselves their daily insulin injections. Product demonstrations will be taking place in the BD booth at the American Diabetes Association 73rd Scientific Sessions on June 21 25, 2013 in Chicago.

Insulin is a life-saving drug for those unable to regulate their blood sugar levels. For many people with diabetes, this means they will take the medication for the rest of their lives, often with multiple injections per day. People with diabetes recognize the impact of BD’s latest innovation on their daily injection experience, with a majority preferring BD Ultra-Fine Nano 4mm Pen Needles with EasyFlow Technology to their current pen needle on all three of the leading insulin pen brands.[1] In a clinical study published in Clinical Therapeutics, 61% of patients reported they needed less thumb force to inject, 1 and 49% of patients reported less time to inject than with their usual pen needle.1 BD is able to deliver this improved performance by increasing the space inside the needle while maintaining industry leading gauge size increasing the flow rate in controlled laboratory testing by up to 149% versus competitive pen needles.1

The launch of EasyFlow Technology is the latest example of BD’s commitment to improving injections for people with diabetes. It follows BD’s recent launch of PentaPoint™ Comfort, a patented 5-bevel needle tip clinically proven to enhance comfort.[2] Both of theseinnovations are now included in BD’s shortest and thinnest pen needle, the BD Ultra-Fine Nano 4mm Pen Needle.

“Building on the introduction of BD’s 4mm needle and 5-bevel PentaPoint Comfort design, we are confident that our new EasyFlow Technology will provide the most comfortable injection experience to help enable patients to adhere more easily to their therapy regimens and ultimately improve their outcomes,” said Linda Tharby, President, BD Medical Diabetes Care.

BD’s steady pace of patient friendly enhancements has caught the attention of some important audiences. For example, BD Ultra-Fine Nano 4mm Pen Needles with EasyFlow Technology have earned the Arthritis Foundation Ease-of-Use Commendation, which recognizes products proven to make life easier for people who have arthritis and other physical limitations. Independently tested by experts and evaluated by people with arthritis, EasyFlow Technology was commended for ease of use when attaching, injecting, and dispensing medication on select insulin pens for people with dexterity challenges.

EasyFlow Technology is currently available in the U.S. and Canada on all BD Ultra-Fine Nano 4mm Pen Needleswith PentaPoint Comfort and will be available in many European countries in the coming months. For more information on how EasyFlow Technology and other BD innovations can help improve outcomes for people with diabetes, visit bd.com/nano.

About Diabetes
Diabetes is a disease in which the body has a shortage of insulin or a decreased ability to use insulin, a hormone that allows glucose (sugar) to enter cells and be converted to energy. When diabetes is not controlled, glucose and fats remain in the blood and, over time, damage vital organs. Diabetes has become a national health concern in the United States, with an estimated 26 million people - 8.3 percent of the population - living with the disease. Of those people, an estimated 18.8 million have been diagnosed with diabetes, and another 7 million are thought to be undiagnosed. If current trends continue, as many as one in three U.S. adults will have diabetes by 2050.[3] The total annual cost of diagnosed diabetes in the United States is an estimated $245 billion.[4]

For nearly 90 years, BD’s culture of innovation and continuous improvement has enhanced the patient experience to help improve therapy and outcomes for people with diabetes worldwide. BD devices support earlier initiation and better adherence to prescribed therapies to help all diabetes patients live healthier lives.

About BD
BD (bd.com) is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

[1]Aronson R., et al. (2013). Insulin pen needles: Effects of extra thin-wall needle technology on preference, confidence, and other patient ratings. Clinical Therapeutics, In Press, Corrected Proof, Available online 20 June 2013
[2]Hirsch L.J., et al. (2012). Impact of a Modified Needle Tip Geometry on Penetration Force as well as Acceptability, Preference, and Perceived Pain in Subjects with Diabetes. Journal of Diabetes Science and Technology, 6(2), 328-35.
[3]Boyle, J.P., Thompson, T.J., Gregg, E.W., et al. (2010). Projection of the year 2050 burden of diabetes in the U.S. adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population Health Metrics.
[4]American Diabetes Association. (2013). Economic Costs of Diabetes in the U.S. in 2012. Diabetes Care.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Becton, Dickinson and Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BD Medical Announced the U.S. Launch of the BD Ultra-Fine™ Nano™ 4mm Pen Needle with EasyFlow™ Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BD | EasyFlow Technology
Publisher Contact: Lindsay Roman - BD.com 
201-847-4312 Lindsay_Roman[.]bd.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Becton, Dickinson and Company / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)